AU · rank #13 · 2026-10-19
EOLS
NASDAQ · $511M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.145 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.186 |
| Analyst upside Consensus target $15.00 | +111.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +19.57% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +66.4% |
| 52w high | $9.31 |
| Market cap (USD) | $511M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Evolus Inc (EOLS) is a commercial-stage performance aesthetics company marketing Jeuveau botulinum toxin and developing the Evolysse hyaluronic acid filler line and Profhilo injectables [1].
Rationale
The analyst upside thesis is strongly reinforced by 100% positive 30-day EPS revision agreement, a 52.6% Q2 earnings surprise, and a full-year 2026 revenue guidance raise to $330–337 million [1].
Material risks
- 1Heavy operational reliance on single-source third-party manufacturer Daewoong for Jeuveau supply creates significant production disruption and partner-execution risk [1].
- 2Intense competition from dominant market leader AbbVie (Botox) and longer-duration entrant Daxxify could trigger price compression and slow Jeuveau market-share expansion [1].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.